- Consumer Products
- Latest 7.12
- Currency US$
- Change 0.04
- Percent Change 0.565 %
- Volume 5,226,815
- Fri Mar 7, 2014 04:00 PM EST NASDAQ data delayed 15 minutes.
12 months ended Sep 30, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
|Earnings||Feb 27||$0.15||May 1||$-0.10|
12 months ended Mar 08, 2014.
A look at major corporate events and financial announcements that are coming up.
About the Company
Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase three clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.